Author of

• 32099

  +

  EP1.12 - Small Cell Lung Cancer/NET (ID 202)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Small Cell Lung Cancer/NET
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32126

    +

    EP1.12-24 - Efficacy of Chemotherapy in Small Cell Lung Cancer: Second Line and Beyond (Now Available) (ID 1962)

    08:00 - 18:00  |  Author(s): selami Bayram
    • Abstract
    • Slides

    Background
    

    Small cell lung cancer (SCLC) is aggressive neuroendocrine carcinoma; despite of chemo sensitivity at first line, almost all cases will be relapsed in 10-12 months. In the absence of checkpoint inhibitors, chemotherapy (CT) is single choice for refractory pts.

    Method
    

    A single center, retrospective analysis was performed to assess the survival data of 2^ndline and beyond CT in the pts with SCLC. The patients' characteristics were recorded. Kaplan meier survival rates were calculated.

    Result
    

    

    A total of 52 (Female/Male:14/38) pts were evaluated. Median age was 64±7(range:47-77) years. Median follow-up was 9 (range:0-51) months. ECOG PS were 0,1 and 2 (9,34 and 9 pts), respectively. At the time of diagnosis, 15 (28.8%) pts were limited, 37 (71.2%) pts were extensive stage. Brain metastases were observed in 8 (15.4%) pts. 14 pts with limited stage disease were received chemoradiotherapy. Profilactic cranial radiation was administered all responders. Platinum and etoposid (PE) combination was the first line CT regimen. ORR was 61.6% (CR:46.2%, PR:15.4%). 31 pts were received 2^ndline CT. Irınotekan (16 pts), topotecan (6 pts), PE (6 pts), platin-paclitaxel (5 pts) were 2^ndline CT regimens. 5 pts were received 3^rd, 2 pts were received 4^thline CT. Median OS was 8.5±1.9 (95%CI:4.8-12.2) months for all pts. Median OS 14±3.8 (95%CI:6.4-21.5) and 6.9±1.9(95%CI: 3-17) months, for limited and extensive stage, respectively. Median PFS (for first line therapy) were 8.8, 7.7 and 8.1 months for limited, extensive and all pts. For second line treatment, median PFS was 5 months. For pts who had received 2 and above line CT, median OS was 14±2 (95%CI:10-17.8) months (Fig1). 5 pts were received 3^rdline CT, 2 of 5 pts were survived 25 and 51 months. 14 (34%) pts had achieved 1 year and longer survival. Most of these 14 pts were limited stage and platinum-sensitive and had received at least 2 lines CT (13/14 pts).

    Conclusion
    

    Despite of high response rates, prognosis is still poor in SCLC. Because of high tumor mutation burden, adding immunotherapy to CT had improved survival. However, some pts cannot be reached immunotherapy in the worldwide. In the absence of checkpoint inhibitor for some countries, with 2-3 line CT regimens (platin based, irinotecan/topotecan and paclitaxel agents), the pts could be survived ≥12 months. Irinotecan and topotecan seems most effective agents for refractory pts. Median PFS for the pts received 2nd line CT was 5 months and it was similar to literature.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.